Starting July 1, 2026, some Medicare beneficiaries will be able to get GLP-1 prescription medications for weight loss with a $50 monthly copay through a short-term pilot called the Medicare GLP-1 Bridge. The program runs through Dec. 31, 2027, and is intended to “bridge” to a potential longer-term program after 2027.
What the program covers
– Covered medications: GLP-1 drugs approved for weight loss, including pill and injectable Wegovy formulations, the KwikPen formulation of Zepbound, and the Foundayo pill.
– Enrollment requirement: You must be enrolled in a Medicare Part D plan to use the Bridge program.
Who is eligible
– Eligibility is based mainly on body mass index (BMI) and health conditions.
– Qualify automatically with BMI ≥ 35. People with BMI ≥ 27 may qualify if they have a qualifying condition such as heart disease or prediabetes.
– About 40% of U.S. adults had obesity (BMI ≥ 30) in recent CDC data, so many Medicare beneficiaries could meet BMI-based criteria.
How it works (unusual process)
– Although Part D enrollment is required, prescriptions and prior authorizations for the Bridge go through a central system run by CMS contractor Humana rather than each beneficiary’s regular Part D plan.
– Doctors submit prior authorization requests to the centralized system. Prescribers do not need to be enrolled Medicare providers to submit requests.
– Once approved, beneficiaries pay a flat $50 copayment at the pharmacy.
Benefits
– The predictable $50 copay could make GLP-1s accessible to patients who could not afford current cash prices, which commonly range from roughly $149 to $699 per month depending on drug and dose.
– The Bridge copay does not increase with higher doses, which matters because many users need higher doses to maintain weight loss.
Drawbacks and limits
– The $50 copay does not count toward the Part D deductible or the annual out-of-pocket cap on prescription drug costs.
– The Bridge program is temporary and ends Dec. 31, 2027. Many people regain weight when they stop GLP-1 therapy, so the limited duration is a concern.
– Beneficiaries who receive the low-income subsidy (Medicare Extra Help) cannot use that assistance for drugs covered by the Bridge program; those used to $5–$10 copays may find $50 unaffordable.
– If a GLP-1 is prescribed for another qualifying condition (Type 2 diabetes, cardiovascular risk reduction, sleep apnea, etc.), it will continue to be covered through the patient’s regular Part D plan and may cost more than $50 under that plan.
Continuity for current users
– People already taking a GLP-1 for weight loss may qualify for the Bridge if the prescriber attests that the patient met the clinical criteria when therapy began (for example, met a BMI threshold at treatment start even if weight has since decreased).
What happens after 2027
– The administration originally proposed a two-step expansion: short Bridge followed by a longer-term program shifting costs to insurers. A voluntary insurer program did not attract enough participation, so CMS extended the Bridge to 18 months.
– CMS has not released cost projections. Analysts have said a longer-term insurer-focused model would have cost insurers billions in year one, and the Bridge itself will be expensive for Medicare because it heavily subsidizes these drug costs.
– How expensive depends on uptake; prior analyses indicate millions of Medicare beneficiaries could be clinically eligible.
Additional notes
– Cash prices listed on government discount sites vary by dose; at higher doses the daily or monthly cost can be much higher than lower-dose introductory pricing.
– The Bridge program uses a flat $50 copay for weight-loss indications only; the same drug may cost different amounts depending on the diagnosis.
If you are on Medicare and interested in getting a GLP-1 for weight loss, check with your Part D plan and your prescriber about prior authorization procedures and whether you meet the Bridge clinical criteria.
